ALG 10000
Alternative Names: ALG-10000Latest Information Update: 09 Jul 2021
At a glance
- Originator Aligos Therapeutics
- Class Antivirals; Oligonucleotides
- Mechanism of Action Hepatitis B surface antigen expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 21 Jun 2021 Pharmacodynamics data from in vitro studies in Hepatitis B presented at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2021 (ILC 2021)
- 27 Aug 2020 Preclinical trials in Hepatitis B in USA (unspecified route)
- 22 Jan 2019 Aligos Therapeutics in-licenses modified nucleic acid technology from Luxiana Biotech